ClinicalTrials.gg
CompletedNCT03487081Updated Jan 23, 2020

Neural Predictors of Social Emotion Regulation Training

An interventional study of Social regulation and Self regulation in Emotions and Rumination, sponsored by Columbia University. Completed at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-23.

Sponsored by Columbia University · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the basic psychological and neural mechanisms underlying the social regulation of emotion - that is, how one person's actions can impact, or regulate - the emotions of another person - and how this ability changes with practice. As such, this study is not designed to directly address clinical health outcomes and provide no treatment or intervention.

Read the detailed description

Prior research has demonstrated that helping others regulate their emotions has benefits for the support provider. But little is known about the basic brain mechanisms underlying this ability or how this ability can change with practice. To address these questions, this study has two parts. In the first, functional magnetic resonance imaging (fMRI) is used to gain insight into the brain systems involved in helping others regulate negative emotions by comparing them to the brain systems involved in regulating the participants' own negative emotions. In the second part, participants engage in three weeks of structured practice, or training, in either socially regulating others' emotions or in self-regulating their own emotions. The investigators predict that helping others regulate their emotions will involve many of the same brain regions implicated in regulating one's own emotions, in addition to regions involved in perspective taking and the reward of helping others. Further, when relating the brain data from part 1 to the regulation practice data from part 2, the investigators expect that individuals who in part 1 show greater activity in brain regions supporting either social or self-regulation may be more likely in part 2 to show corresponding improvements in regulation performance. The results of these studies are intended to lay the groundwork for future studies investigating the social regulation of emotion in older adults and clinical populations for whom social support can be beneficial.

02

Conditions studied

  • Emotions
  • Rumination
03

In context

Lead sponsor

Columbia University is the lead sponsor of 1,136 studies on the registry; 195 are open to participants now.

Of its 182 completed or terminated interventional studies of FDA-regulated products, 150 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Native English speaker
  • Right handed

Exclusion criteria

Exclusion Criteria:

  • Current or past history of neurological or psychiatric illness
  • Use of psychoactive drugs
  • Individuals who have metal devices or implants that cannot be removed from their body (e.g., piercings, pacemakers, copper intrauterine devices (IUDs))
  • Pregnant women
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Social regulation

    Following the fMRI session, participants in the social regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will receive one event written by another participant. They will be asked to help the other person use emotion regulation strategies to feel less negative. The participant will answer brief questions related to his/her feelings after receiving the event and after providing social emotion regulation.

    Behavioral: Social regulation

  • Active comparator
    Self regulation

    Following the fMRI session, participants in the self regulation group will be asked to rate their mood twice a day for 3 weeks. Furthermore, every other day, they will write an event that caused them negative emotions. They will be asked to use emotion regulation strategies to decrease their negative emotions. The participant will answer brief questions related to his/her feelings after writing the event and after implementing the emotion regulation strategy.

    Behavioral: Self regulation

Interventions

  • BehavioralSocial regulation

    Participants will be instructed to help another person think about their negative events differently using an emotion regulation strategy called reappraisal.

  • BehavioralSelf regulation

    Participants will be instructed to think about their negative events by reframing the meaning of the event. This is a typical strategy in emotion regulation research known as reappraisal.

06

What researchers measure

Primary outcomes

  1. Emotion Regulation Questionnaire (ERQ) Score

    The Emotion Regulation Questionnaire (10 items) has 2 subscales - suppression and reappraisal. Participants rate their response on a 7-point Likert scale ranging from 1 (Strongly disagree) to 7 (Strongly agree). The total score is calculated from the sum of the items in each subscale. Higher scores indicate higher tendency to use the emotion regulation strategy.

    Time frame: Change from baseline at 3 weeks follow up

  2. Ruminative Response Scale (RRS) Score

    The Ruminative Response Scale (22 items) has 3 subscales - brooding, reflection and depression. Participants rate their response on a 4-point Likert scale ranging from 1 (Almost never) to 4 (Almost always). The total score is calculated from the sum of the items in each subscale. Higher scores indicate higher tendency to engage in ruminative thoughts.

    Time frame: Change from baseline at 3 weeks follow up

Secondary outcomes

  1. Change in mood rating (Likert scale score)

    Participants rate their response indicating their current emotions (e.g., angry, happy, sad) on a 9-point Likert scale ranging from 1 (completely disagree) to 9 (completely agree). The total score for positive mood is calculated from the sum of 4 positive emotion items. The total score for negative mood is calculated from the sum of 4 negative emotion items.

    Time frame: Baseline, up to 3 weeks

  2. Change in Brief State Rumination Inventory (BSRI) (Likert scale score)

    Participants rate their response indicating their ruminative thought (e.g., "Right now, I wonder why I react the way I do") on a 9-point Likert scale ranging from 1 (completely disagree) to 9 (completely agree). The total score is calculated from the sum of all 13 items.

    Time frame: Baseline, up to 3 weeks

  3. State Trait Anxiety Inventory (STAI) - Trait Scale (Likert scale score)

    The State Trait Anxiety Inventory - Trait scale (20 items) measures trait anxiety. Participants rate their response on a 4-point Likert scale ranging from 1 (Almost never) to 4 (Almost always). The total score is calculated from the sum of all items. Higher scores indicate higher anxiety.

    Time frame: Change from baseline at 3 weeks follow up

  4. Center for Epidemiologic Studies Depression Scale (CES-D) (Likert scale score)

    The Center for Epidemiologic Studies Depression Scale (20 items) measures depression. Participants rate their response on a 4-point Likert scale ranging from 0 (Rarely or none of the time (less than 1 day)) to 3 (All of the time (5-7 days)). The total score is calculated from the sum of all items. Higher scores indicate higher depression level.

    Time frame: Change from baseline at 3 weeks follow up

07

Study locations

1 site
  • Columbia University
    New York, New York 10027, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Feb 2019, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2018
First posted
Apr 3, 2018
StartActual
Jul 2, 2018
Primary completionActual
Feb 11, 2019
CompletionActual
Feb 11, 2019
Last update
Jan 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03487081
Responsible party
Kevin Ochsner (Professor of Psychology, Columbia University) — Principal investigator
First posted
Apr 3, 2018
Start date
Jul 2, 2018
Primary completion
Feb 11, 2019
Completion
Feb 11, 2019
Last update
Jan 23, 2020

Study contacts

Kevin Ochsner, PhD
principal investigator · Department of Psychology, Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion